Cwm, LLC Genmab A/S Transaction History

Cwm, LLC

$33.3 Billion
Q3 2025

A detailed history of Cwm, LLC transactions in Genmab A/S stock. As of the latest transaction made, Cwm, LLC holds 2,306 shares of GMAB stock, worth $65,974. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,306

Previous 1,797 28.32%

Holding current value

$65,974

Previous $37,000 91.89%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 15, 2025	BUY	$20.3 - $30.67 $10,332 - $15,611	509 Added 28.32%	2,306 $71,000
Q2 2025 Jul 25, 2025	BUY	$17.98 - $23.09 $10,841 - $13,923	603 Added 50.5%	1,797 $37,000
Q1 2025 May 01, 2025	SELL	$18.69 - $24.14 $15,325 - $19,794	-820 Reduced 40.71%	1,194 $23,000
Q4 2024 Feb 04, 2025	BUY	$20.02 - $24.15 $14,254 - $17,194	712 Added 54.69%	2,014 $42,000
Q3 2024 Oct 08, 2024	BUY	$23.84 - $28.48 $7,533 - $8,999	316 Added 32.05%	1,302 $32,000
Q2 2024 Jul 09, 2024	BUY	$25.13 - $30.27 $2,538 - $3,057	101 Added 11.41%	986 $25,000
Q1 2024 Apr 05, 2024	SELL	$26.43 - $32.77 $294,535 - $365,188	-11,144 Reduced 92.64%	885 $26,000
Q4 2023 Feb 01, 2024	SELL	$27.94 - $35.44 $48,252 - $61,204	-1,727 Reduced 12.55%	12,029 $383,000
Q3 2023 Oct 11, 2023	BUY	$35.27 - $42.24 $26,769 - $32,060	759 Added 5.84%	13,756 $485,000
Q2 2023 Aug 03, 2023	BUY	$37.4 - $42.94 $97,165 - $111,558	2,598 Added 24.98%	12,997 $494,000
Q1 2023 Apr 28, 2023	BUY	$34.88 - $43.22 $100,000 - $123,911	2,867 Added 38.06%	10,399 $393,000
Q4 2022 Feb 01, 2023	SELL	$33.8 - $47.06 $50,699 - $70,590	-1,500 Reduced 16.61%	7,532 $319,000
Q3 2022 Oct 27, 2022	SELL	$31.52 - $373.61 $51,881 - $614,962	-1,646 Reduced 15.41%	9,032 $290,000
Q2 2022 Jul 28, 2022	SELL	$26.83 - $38.57 $72,360 - $104,023	-2,697 Reduced 20.16%	10,678 $347,000
Q1 2022 Apr 21, 2022	SELL	$30.95 - $39.68 $105,044 - $134,673	-3,394 Reduced 20.24%	13,375 $484,000
Q4 2021 Jan 31, 2022	SELL	$35.87 - $47.12 $121,455 - $159,548	-3,386 Reduced 16.8%	16,769 $663,000
Q1 2021 Sep 15, 2021	SELL	$30.92 - $44.4 $120,340 - $172,804	-3,892 Reduced 16.18%	20,155 $823,000
Q1 2021 Apr 27, 2021	BUY	$30.92 - $44.4 $120,340 - $172,804	3,892 Added 19.31%	24,047 $789,000
Q4 2020 Sep 15, 2021	SELL	$33.66 - $40.76 $24,403 - $29,551	-725 Reduced 3.47%	20,155 $823,000
Q4 2020 Jan 27, 2021	BUY	$33.66 - $40.76 $24,403 - $29,551	725 Added 3.6%	20,880 $849,000
Q3 2020 Sep 15, 2021	BUY	$33.07 - $38.68 $666,525 - $779,595	20,155 New	20,155 $823,000
Q3 2020 Oct 19, 2020	SELL	$33.07 - $38.68 $666,525 - $779,595	-20,155 Closed	0 $0
Q2 2020 Sep 15, 2021	BUY	$20.05 - $33.89 $404,107 - $683,052	20,155 New	20,155 $823,000
Q2 2020 Jul 22, 2020	SELL	$20.05 - $33.89 $404,107 - $683,052	-20,155 Closed	0 $0
Q1 2020 Sep 15, 2021	BUY	$17.15 - $25.22 $345,658 - $508,309	20,155 New	20,155 $823,000
Q1 2020 Apr 28, 2020	SELL	$17.15 - $25.22 $345,658 - $508,309	-20,155 Closed	0 $0
Q4 2019 Sep 14, 2021	BUY	$18.88 - $24.14 $380,526 - $486,541	20,155 New	20,155 $823,000
Q4 2019 Jan 27, 2020	SELL	$18.88 - $24.14 $380,526 - $486,541	-20,155 Closed	0 $0
Q3 2019 Sep 14, 2021	BUY	$18.0 - $21.38 $362,790 - $430,913	20,155 New	20,155 $823,000
Q3 2019 Oct 22, 2019	SELL	$18.0 - $21.38 $362,790 - $430,913	-20,155 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$16.37 - $18.47 $329,937 - $372,262	20,155 New	20,155 $823,000
Q2 2019 Jul 31, 2019	SELL	$16.37 - $18.47 $329,937 - $372,262	-20,155 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$14.53 - $17.93 $292,852 - $361,379	20,155 New	20,155 $0

Others Institutions Holding GMAB

# of Institutions

252

Shares Held

65.2M

Call Options Held

32.5K

Put Options Held

55K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $18.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account